Research on the Economic Burden and Misdiagnosis Costs of Alzheimer’s Disease Presented at AAIC 2014
July 24, 2014
Alzheimer's disease research conducted by a team from Analysis Group and Eli Lilly and Company was presented at the Alzheimer's Association International Conference (AAIC) in Copenhagen, Denmark, on July 16, 2014. Analysis Group Manager Noam Kirson presented "Assessing the Economic Burden of Alzheimer's Disease Patients Treated by Specialists on the Date of Preliminary Diagnosis of Cognitive Decline" during the conference's health economics and policy session. The research -- funded by Eli Lilly and conducted by an Analysis Group team including Dr. Kirson, Principal Howard Birnbaum, and Associate Urvi Desai -- compared the health care resource use and costs of patients with Alzheimer's disease who were seen by a specialist at the time of first diagnosis of cognitive decline with patients who were not initially seen by a specialist. The study found that patients not initially seen by a specialist incurred higher health care costs in the year following diagnosis.
In addition, a poster based on a separate research study conducted by an Analysis Group team including Drs. Kirson, Birnbaum, and Desai, also in collaboration with Eli Lilly, was presented at the conference. This study, "Excess Costs Associated with Possible Misdiagnosis of Alzheimer's Disease among Patients with Vascular Dementia in a UK CPRD Population," examined how the misdiagnosis of Alzheimer's disease in patients in the United Kingdom that were later diagnosed with vascular dementia led to excess costs of care. The results were similar to those found in a U.S.-based study conducted by a joint team from Analysis Group and Eli Lilly and presented at last year's AAIC.